Immunohistochemical Double Staining Technique To Screen Patients With Non-small Cell Lung Cancer Suitable For PD-L1 Inhibitor Therapy

Use immunohistochemistry technology to establish a PD-L1/TTF-1 and PD-L1/P40 immunohistochemical double staining model,so as to accurately screen the population with high PD-L1 expression in non-small cell lung cancer,for clinical immunization Checkpoint inhibitor therapy provides accurate laboratory test results.The PD-L1/TTF-1 and PD-L1/P40 immunohistochemical double-staining methods were established to run staining of 25 cases of lung adenocarcinoma and 25 cases of lung squamous cell carcinoma.The expression of the two groups of antibodies in adenocarcinoma and squamous cell carcinoma were observed in situ in the same section,cancer cells were identified accurately based on the expression and location of TTF-1 and P40,and then the proportion of PD-L1 positive cells in cancer cells(Tumor Proportion Score,TPS)was analyzed with statistical methods.The experimental results showed that PD-L1 is expressed in tumor cells and immune cells,while P40 and TTF-1 are only expressed in cancer cells.There was no statistically significant difference in TPS scores between PD-L1 single staining and PD-L1/P40 double staining in lung squamous cell carcinoma(P=0.357),and there was no statistically significant difference in TPS scores between PD-L1 single staining and PD-L1/TTF-1 double staining in lung adenocarcinoma(P=0.112).Therefore,the immunohistochemical double staining technique can effectively use one of the antibodies TTF-1 or P40 to locate cancer cells,and eliminate the deviation of TPS caused by non-cancer PD-L1 staining,which is beneficial to accurately assess the authenticity of PD-L1 in cancer cells.The expression status has important reference value and guiding significance for the follow-up treatment strategies and prognosis evaluation of patients with non-small cell lung cancer.